Parameters that determine dissolution and efficacy of itraconazole and its relevance to recalcitrant dermatophytoses

References

• Sardana K, Khurana A. Overview of causes and treatment of recalcitrant dermatophytoses. Sardana K, Khurana A, Garg S, et al., editors. IADVL manual on management of dermatophytoses. 1st. Delhi: CBS; 2018; p. 80–105.
   Google Scholar
• Singh A, Masih A, Khurana A, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the Squalene epoxidase (SQLE) gene. Mycoses. 2018;61(7):477–484.
   PubMed Web of Science ®Google Scholar
• Khurana A, Masih A, Chowdhary A, et al. Correlation of in vitro susceptibility based on MICs and squalene epoxidase mutations with clinical response to terbinafine in patients with tinea corporis/cruris. Antimicrob Agents Chemother. 2018;62(12):e01038–18.
   PubMed Web of Science ®Google Scholar
• Sardana K, Khurana A, Singh A, et al. A pilot analysis of morphometricassessment of itraconazole brands using dermoscopy and its relevance in the current scenario. Indian Dermatol Online J. 2018;9(6):426–431.
   PubMedGoogle Scholar
• Ac P, Dw D. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents. 2007;30(1):93–94.
   PubMed Web of Science ®Google Scholar
• Sherrington PJ, Oliver R. Compaction and other granulation methods. In: Goldberg AS, editor. Granulation. London, Philadelphia: Heyden; 1981. p. 141–152.
   Google Scholar
• Kristensen HG, Granulation: ST. A review of pharmaceutical wet granulation. Drug Dev Ind Pharm. 1987;13:803–872.
   Web of Science ®Google Scholar
• Conine JW, Hadley HR Preparation of small solid pharmaceutical spheres. Drug Cosmet Ind. 90: 38–41(1970).
   Google Scholar
• Vasconcelos T, Marques S, Das Neves J, et al. Amorphous solid dispersions: rational selection of a manufacturing process. Adv Drug Deliv Rev. 2016;100:85–101.
   PubMed Web of Science ®Google Scholar
• Marsac PJ, Rumondor ACF, Nivens DE, et al. Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly(vinyl pyrrolidone). J Pharm Sci. 2010;99:169–185.
   PubMed Web of Science ®Google Scholar
• Singh A, Bharati A, Frederiks P, et al. Effect of compression on the molecular arrangement of itraconazole–soluplus solid dispersions: induction of liquid crystals or exacerbation of phase separation? Mol Pharm. 2016;13:1879–1893.
   PubMed Web of Science ®Google Scholar
• Allegra S, Fatiguso G, De Francia S, et al. Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. Clin Exp Pharmacol Physiol. 2017;44:1083–1088.
   PubMed Web of Science ®Google Scholar
• Purohit HS, Ormes JD, Saboo S, et al. Insights into nano- and micron-scale phase separation in amorphous solid dispersions using fluorescence-based techniques in combination with solid state nuclear magnetic resonance spectroscopy. Pharm Res. 2017;34:1364–1377.
   PubMed Web of Science ®Google Scholar
• Ricarte RG, Lodge TP, Hillmyer MA. Detection of pharmaceutical drug crystallites in solid dispersions by transmission electron microscopy. Mol Pharm. 2015;12:983–990.
   PubMedGoogle Scholar
• Li N, Gilpin CJ, Taylor LS. Understanding the impact of water on the miscibility and microstructure of amorphous solid dispersions: an AFM-LCR and TEM-EDX study. Mol Pharm. 2017;14:1691–1705.
   PubMed Web of Science ®Google Scholar
• Démuth B, Farkas A, Pataki H, et al. Detailed stability investigation of amorphous solid dispersions prepared by single-needle and high speed electrospinning. Int J Pharm. 2016;498:234–244.
   PubMedGoogle Scholar
• Trasi NS, Purohit HS, Wen H, et al. Non-sink dissolution behavior and solubility limit of commercial tacrolimus amorphous formulations. J Pharm Sci. 2017;106:264–272.
   PubMed Web of Science ®Google Scholar
• Bhardwaj V, Trasi NS, Zemlyanov DY, et al. Surface area normalized dissolution to study differences in itraconazole-copovidone solid dispersions prepared by spray-drying and hot melt extrusion. Int J Pharm. 2018;540(1–2):106–119.
   PubMedGoogle Scholar
• Scholz P, Keck CM. Nanocrystals: from raw material to the final formulated oral dosage form-a review. Curr Pharm Des. 2015;21:4217–4228.
   PubMed Web of Science ®Google Scholar
• Cal K, Sollohub K. Spray drying technique. I: hardware and process parameters. J Pharm Sci. 2010;99:575–586.
   PubMed Web of Science ®Google Scholar
• Chin WWL, Parmentier J, Widzinski M, et al. A brief literature and patent review of nanosuspensions to a final drug product. J Pharm Sci. 2014;103:2980–2999.
   PubMed Web of Science ®Google Scholar
• Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65:315–499.
   PubMed Web of Science ®Google Scholar
• Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62:3–16.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Van Den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364(1):64–75.
   PubMed Web of Science ®Google Scholar
• Felton LA. Film coating of oral solid dosage form. Swarbrick J, editor. Encyclopedia of pharmaceutical technology. 3rd. New York (NY): Informa Healthcare; 2007; p. 1729–1747.
   Google Scholar
• Woodruff CW, Nuessle NO. Effect of processing variables on particles obtained by extrusion-spheronization processing. J Pharm Sci. 1972;61:787–790.
   PubMed Web of Science ®Google Scholar
• Fonner DE, Anderson RN, Banker SG. Granulation and tablet characteristics. In: Lachman L, editor. Pharmaceutical dosage forms: tablets. New York (NY): Marcel Dekker; 1981. p. 185–266.
   Google Scholar
• Costa FO, Pais AACC, Sousa JJS. Analysis of formulation effects in the dissolution of ibuprofen pellets. Int J Pharm. 2004;270:9–19.
   PubMedGoogle Scholar
• Mehta MA. Evaluation and characterization of pellets. In: Ghebre-Sellassie I, editor. Pharmaceutical pelletization technology. New York (NY): CRC press; 1989. p. 241–265.
   Google Scholar
• Millili GP, Schwartz JB. The strength of microcrystalline cellulose pellets the effect of granulating with water/ethanol mixtures. Drug Dev Ind Pharm. 1990;16:1411–1426.
   Web of Science ®Google Scholar
• Bianchini R, Bruni G, Gazzaniga A, et al. Influence of extrusion-spheronization processing on the physical properties of dindobufen pellets containing pH adjusters. Drug Dev Ind Pharm. 1992;18:1485–1503.
   Web of Science ®Google Scholar
• Baert L, Vermeersch H, Remon JP, et al. Study of parameters important in the spheronization process. Int J Pharm. 1993;96:225–229.
   Web of Science ®Google Scholar
• Bataille B, Ligarski K, Jacob M, et al. Study of the influence of spheronization and drying conditions on the physicomechanical properties of neutral spheroids containing Avicel PH 101 and lactose. Drug Dev Ind Pharm. 1993;19:653–671.
   Web of Science ®Google Scholar
• O‘Connor RE, Schwartz JB, Spheronization II. Drug release from drug diluent mixtures. Drug Dev Ind Pharm. 1985;11:1837–1857.
   Web of Science ®Google Scholar
• Zhang G, Schwartz JB, Schnaare RL. Effect of spheronization technique on drug release from uncoated beads. Drug Dev Ind Pharm. 1990;16:1171–1184.
   Web of Science ®Google Scholar
• Newman D, Engers S, Bates I, et al. Characterization of amorphous API: polymer mixtures using X-ray powder diffraction. J Pharm Sci. 2008;97:4840–4856.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Sangwai M, Wawdhane S, et al. Soluble itraconazole in tablet form using disordered drug delivery approach: critical scale-up considerations and bio-equivalence studies. AAPS PharmSciTech. 2013;14(1):360–374.
   PubMed Web of Science ®Google Scholar
• Parmentier J, Tan EH, Low A, et al. Downstream drug product processing of itraconazole nanosuspension: factors influencing drug particle size and dissolution from nanosuspension-layered beads. Int J Pharm. 2017;524(1–2):443–453.
   PubMedGoogle Scholar
• Kayaert P, Van Den Mooter G. Is the amorphous fraction of a dried nanosuspension caused by milling or by drying? A case study with Naproxen and Cinnarizine. Eur J Pharm Biopharm. 2012;81(3):650–656.
   PubMed Web of Science ®Google Scholar
• Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785–796.
   PubMed Web of Science ®Google Scholar
• Zhang K, Yu H, Luo Q, et al. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension. Eur J Pharm Biopharm. 2013;85:1285–1292.
   PubMed Web of Science ®Google Scholar
• Peeters J, Neeskens P, Tollenaere JP, et al. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci. 2002;91:1414–1422.
   PubMed Web of Science ®Google Scholar
• Mellaerts R, Mols R, Jammaer JAG, et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm. 2008;69:223–230.
   PubMed Web of Science ®Google Scholar
• Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother. 1998;42:1862–1865.
   PubMed Web of Science ®Google Scholar
• Willems L, van derGeest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001;26:159–169.
   PubMed Web of Science ®Google Scholar
• Brouwers J, Geboers S, Mols R, et al. Gastrointestinal behavior of itraconazole in humans–part 1: supersaturation from a solid dispersion and a cyclodextrin-based solution. Int J Pharm. 2017;525(1):211–217.
   PubMedGoogle Scholar
• Kohri N, Yamayoshi Y, Xin H, et al. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol. 1999;51:159–164.
   PubMed Web of Science ®Google Scholar
• Kondo N, Iwao T, Hirai KI, et al. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci. 1994;83:566–570.
   PubMed Web of Science ®Google Scholar
• Miller DA, DiNunzio JC, Yang W, et al. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res. 2008;25:1450–1459.
   PubMed Web of Science ®Google Scholar
• Lentz KA. Current methods for predicting human food effect. AAPS J. 2008;10:282–288.
   PubMed Web of Science ®Google Scholar
• Abuhelwa AY, Foster DJ, Mudge S, et al. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59(9):5681–5696.
   PubMed Web of Science ®Google Scholar
• Thiry J, Broze G, Pestieau A, et al. Investigation of a suitable in vitro dissolution test for itraconazole-based solid dispersions. Eur J Pharm Sci. 2016;85:94–105.
   PubMed Web of Science ®Google Scholar
• Matsui K, Tsume Y, Amidon GE, et al. The evaluation of in vitro drug dissolution of commercially available oral dosage forms for itraconazole in Gastrointestinal Simulator with biorelevant media. J Pharm Sci. 2016;105:2804–2814.
   PubMed Web of Science ®Google Scholar
• Smith D, Velde V, Woestenborghs R, et al. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol. 1992;44:618–619.
   PubMed Web of Science ®Google Scholar
• Bradford CR, Prentice AG, Warnock DW, et al. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother. 1991;28:555–560.
   PubMed Web of Science ®Google Scholar
• Van de Velde V, Van Peer AP, Heykants J, et al. Effect of food on the pharma-cokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy. 1996;16:424–428.
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;14:147–150.
   Google Scholar
• Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 1989;36:423–426.
   PubMed Web of Science ®Google Scholar
• Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1987;37:535–540.
   Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. PharmacolTher. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996;51:585–620.
   PubMed Web of Science ®Google Scholar
• Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32:67–87.
   PubMed Web of Science ®Google Scholar
• Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet. 1998;35:461–473.
   PubMed Web of Science ®Google Scholar
• Sardana K, Arora P, Mahajan K Intracutaneous pharmacokinetics of oralantifungals and their relevance in recalcitrant cutaneous dermatophytosis: timeto revisit basics. Indian J Dermatol VenereolLeprol. 83 (6):730–732 (2017).
   Web of Science ®Google Scholar
• Raab WPE. The treatment of mycosis with imidazole derivatives. In: Raab WPE, editor. The treatment of mycosis with imidazole derivatives. Berlin: Springer; 1980. p. 1–157.
   Google Scholar
• Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 18:263–268 (1988).
   PubMed Web of Science ®Google Scholar
• Piérard G, Arrese J, De Doncker P Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 32:429–435 (1995).
   PubMed Web of Science ®Google Scholar
• De Doncker P. Pharmacokinetics of oral antifungal agents. Dermatol Ther. 1997;3:46–57.
   Google Scholar
• Mrig P, Sardana K. Rationale of use of antifungal drugs based on skin pharmacokinetics. In: Sardana K, Khurana A, Garg S, et al., editors. IADVL manual on management of dermatophytoses. 1st ed. Delhi: CBS; 2018. p. 65–73.
   Google Scholar
• De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol. 37:969–974(1997).
   PubMed Web of Science ®Google Scholar
• Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology. 1994;189:378–381.
   PubMed Web of Science ®Google Scholar
• Gupta AK, De Doncker P, Heremans A, et al. Itraconazole for the treatment of tinea pedis: a dose of 400 mg daily given for 1 week is similar in efficacy to 100 or 200 mg daily given for 2 to 4 weeks. J Am Acad Dermatol.36:789–792 (1997).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ryder JE The use of oral antifungal agents to treat onychomycosis. Dermatol Clin 21:469–479 (2003)
   PubMed Web of Science ®Google Scholar
• Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr Ann. 2005;34:191–200.
   PubMed Web of Science ®Google Scholar
• Ginter-Hanselmayer G, Seebacker C. Treatment of tinea capitis––a critical appraisal. J Dtsch Dermatol Ges. 2011;9:109–114.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Solomon RS, Adam P. Itraconazole oral solution for the treatment of tinea capitis. Br J Dermatol. 1998;139:104–106.
   PubMed Web of Science ®Google Scholar
• Boonk W, Geer D, Kreek E, et al. Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. Mycoses. 1998;41(11‐12):509–514.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Groen K, Woestenborghs R, et al. Itraconazole pulse therapy is effective in the treatment of Majocchi’s granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. Clin Exp Dermatol. 1998;23:103–108.
   PubMed Web of Science ®Google Scholar
• Sardana K, Kaur R, Arora P, et al. Is antifungal resistance a cause for treatment failure in dermatophytosis: a study focused on tinea corporis and cruris from a tertiary centre? Indian Dermatol Online J. 2018;9(2):90–95.
   PubMedGoogle Scholar
• Heinen MP, Cambier L, Antoine N, et al. Th1 and Th17 immune responses act complementarily to optimally control superficial dermatophytosis. J Invest Dermatol. 2018; 139(3), 626–637.
   PubMed Web of Science ®Google Scholar
• Kelly A, Nelson K, Goodwin M, et al. Adverse effects of topical corticosteroids. BMJ. 1972;14:114.
   Google Scholar
• Kerner M, Ishay A, Ziv M, et al. Evaluation of the pituitary-adrenal axis function in patients on topical steroid therapy. J Am A cad Dermatol 65: 215–216(2011).
   PubMed Web of Science ®Google Scholar
• Allenby CF, Main RA, Marsden RA, et al. Effect on adrenal function of topically applied clobetasol propionate (Dermovate). Br Med J. 1975;4:619–621.
   PubMed Web of Science ®Google Scholar
• Cook D FDA experience: topical corticosteroids and HPA axis suppression. FDA pediatric subcommittee of the AIDAC; 2003 Oct 29-30 .
   Google Scholar
• Carruthers JA, August PJ, Staughton RC. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J. 1975;4:203–204.
   PubMedGoogle Scholar